Krystal Biotech, Inc. (KRYS) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Pittsburgh, PA, アメリカ. 現CEOは Krish S. Krishnan.
KRYS を有する IPO日 2017-09-20, 275 名の正社員, に上場 NASDAQ Global Market, 時価総額 $7.89B.
Krystal Biotech, Inc. is a clinical-stage biotechnology company developing redosable gene therapy treatments for serious rare diseases. The company's lead product candidate, beremagene geperpavec (B-VEC), is in Phase III clinical trials for dystrophic epidermolysis bullosa, with additional pipeline programs targeting congenital ichthyosis, aged skin conditions, cystic fibrosis, and Netherton syndrome at various development stages. Founded in 2015 and headquartered in Pittsburgh, Pennsylvania, Krystal Biotech focuses on addressing unmet medical needs in dermatological and genetic disorders through innovative gene therapy approaches.
